open access

Vol 2, No 3 (2001): Practical Diabetology
Review articles (submitted)
Published online: 2001-06-15
Get Citation

Type 2 diabetes treatment improvement after introduction of extended release tablets of glipizide, Glibenese GITS

Władysław Grzeszczak
Diabetologia Praktyczna 2001;2(3):175-182.

open access

Vol 2, No 3 (2001): Practical Diabetology
Review articles (submitted)
Published online: 2001-06-15

Abstract

GITS system gives us unique pharmacokinetic and pharmacodynamic properties. Thanks to GITS it is possible to use short acting glipizide only once a day. Summing up results of performed studies, the introduction of Glibenese GITS into treatment of type 2 diabetes causes: 1) stable concentration of the drug in blood plasma over 24 hours; 2) decreased insulin secretion, necessary for the hypoglycaemic effect, when compared with other sulfonylureas; 3) decreased C-peptide secretion, when compared with other sulfonylureas; 4) decreased hepatic glucose production; 5) significant improvement of metabolic control, when compared to other sulfonylureas; 6) significant improvement of insulin sensitivity; 7) improvement of lipid metabolism; 8) possibility of equally efficient treatment in both younger and older patients; 9) possibility of equally efficient treatment in patients with mild chronic renal failure; 10) decreased risk of hypoglycaemia; 11) improvement of quality of life in type 2 diabetes. Glibenese is a single oral drug which was shown to improve the quality of life in type 2 diabetes. In summary, the Glibenese GITS, generated using the GITS technology, has unique advantages, which might or even should be used in the treatment of type 2 diabetes. Having considered numerous advantages and few disadvantages of the presented drug, we should think about Glibenese GITS, when we start or change the treatment of the type 2 diabetes.

Abstract

GITS system gives us unique pharmacokinetic and pharmacodynamic properties. Thanks to GITS it is possible to use short acting glipizide only once a day. Summing up results of performed studies, the introduction of Glibenese GITS into treatment of type 2 diabetes causes: 1) stable concentration of the drug in blood plasma over 24 hours; 2) decreased insulin secretion, necessary for the hypoglycaemic effect, when compared with other sulfonylureas; 3) decreased C-peptide secretion, when compared with other sulfonylureas; 4) decreased hepatic glucose production; 5) significant improvement of metabolic control, when compared to other sulfonylureas; 6) significant improvement of insulin sensitivity; 7) improvement of lipid metabolism; 8) possibility of equally efficient treatment in both younger and older patients; 9) possibility of equally efficient treatment in patients with mild chronic renal failure; 10) decreased risk of hypoglycaemia; 11) improvement of quality of life in type 2 diabetes. Glibenese is a single oral drug which was shown to improve the quality of life in type 2 diabetes. In summary, the Glibenese GITS, generated using the GITS technology, has unique advantages, which might or even should be used in the treatment of type 2 diabetes. Having considered numerous advantages and few disadvantages of the presented drug, we should think about Glibenese GITS, when we start or change the treatment of the type 2 diabetes.

Get Citation

Keywords

cukrzyca; Glibenese GITS; poprawa skuteczności leczenia

About this article
Title

Type 2 diabetes treatment improvement after introduction of extended release tablets of glipizide, Glibenese GITS

Journal

Clinical Diabetology

Issue

Vol 2, No 3 (2001): Practical Diabetology

Pages

175-182

Published online

2001-06-15

Bibliographic record

Diabetologia Praktyczna 2001;2(3):175-182.

Keywords

cukrzyca
Glibenese GITS
poprawa skuteczności leczenia

Authors

Władysław Grzeszczak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl